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Abstract: Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder that affects 
approximately 14,000 persons each year in the US. AML occurs at all ages but the incidence 
increases with age with the median age at diagnosis being 67 years. Advances in the treatment 
of AML over the past decades have led to improved survival, albeit mostly in younger patients. 
The prognosis of older patients with this disease over the same time span has not changed much 
and remains dismal. This review focuses on the epidemiology and characteristics of AML in 
elderly patients, the rationale for treating elderly AML patients, and the currently available 
and potential future treatment options such as sapacitabine. Elderly AML patients treated with 
intensive chemotherapy have a higher mortality rate, and a lower rate of complete remission 
and overall survival when compared to the younger population. This is due to both the differ-
ent biology of the disease and the number of patient-specific factors. However, elderly AML 
patients treated with aggressive chemotherapy can achieve durable remissions, which offer 
prolonged survival and improved quality of life. Recent data also indicates that elderly AML 
patients deemed unfit for intensive chemotherapy benefit from leukemia-specific attenuated 
dose chemotherapy compared to supportive care alone. This has led to renewed interest to look 
for anti-leukemic therapies designed specifically for older patients. Sapacitabine, a novel oral 
nucleoside analog, promises good efficacy, favorable toxicity profile, and ease of administration; 
all of which makes it very appealing. Results from pre-clinical and clinical studies have been 
very encouraging and sapacitabine is currently being evaluated in a Phase III study, of which 
the results are eagerly awaited.
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Introduction
Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder characterized by 
clonal proliferation of myeloid precursors with an inhibition in differentiation, leading 
to accumulation of immature cells at various stages and reduction in the production of 
normal hematopoietic components: erythrocytes, platelets, and mature granulocytes. 
With an incidence of approximately four per 100,000 per year, AML is relatively 
uncommon but responsible for a large number of cancer-related deaths.1 It is estimated 
that in the US, about 14,590 persons will be diagnosed with and 10,370 will die of 
AML in 2013. The incidence of AML increases with age; the median age at diagnosis 
today is 67 years (Figure 1), making AML truly “a disease of the elderly.”1
The past 4 decades have seen significant advances in the diagnosis and treatment 
of this condition. The succession of clinical trials performed throughout previous 
decades established the standard of care for the treatment of this disease: at present, 



































































Figure 1 Age-specific SEER incidence rates for acute myeloid leukemia, 2006–2010.






















































































Figure 3 Five-year relative survival (percentage) by age of diagnosis, 2003–2009.





as many as 75% of patients with newly diagnosed AML can 
expect to enter remission and as many as 40%–50% can 
expect to survive long-term. However, the great majority of 
patients enrolled in those trials were younger than 60 years 
old, and as expected, the chemotherapy regimens developed 
in the process perform best in the younger patient popula-
tion. Very few older patients can tolerate such intensive 
chemotherapy; those who can, do not respond as well as 
younger patients, relapse sooner, and their long-term prog-
nosis remains poor.
Over the past several years, we have come to a realization 
that improving the outcomes of older patients with AML will 
require approaches specifically developed for them. These 
approaches will need to take into account not only the differ-
ent biology of AML in these patients but also find a way to 
overcome specific host factors such as comorbid conditions, 
overall fitness, and difficult psychosocial aspects. In this 
review, we will provide an overview on the epidemiology and 
characteristics of AML in elderly patients, the rationale for 
treating elderly AML patients, and the potential of sapacit-
abine to become a novel treatment strategy, specifically for 
elderly patients.
Epidemiology and treatment 
outcome in elderly AML patients
Prior to the introduction of effective therapy, AML was a uni-
formly fatal disease, with an expected 5-year survival of less 
than 10%. Over the past 3 decades, the survival rate in AML 
patients gradually increased: according to the  Surveillance, 
Epidemiology and End Results (SEER) program, statistics 
between 2003 and 2009 reached 24.9% (Figure 2).1 The 5-year 
relative survival of younger AML patients actually increased to 
41.6%. At the same time, the 5-year survival of older patients 
aged $65 years remained poor at 5.4% (Figure 3).1 Other 
registries and AML treatment groups confirmed the slow but 
steady improvement over time in the outcomes of younger 
patients coupled with the lack of any appreciable progress in 
older patients (Figure 4).2,3 The newer data also confirmed the 
arbitrary nature of the cut-off we use to define younger and 
older patient populations, which is between 55 and 65 years 
old. It has become apparent that beginning at the age of 30–40 
years old, the increasing age of these patients acts as an inde-
pendent continued variable until well past age 65 years. The 
retrospective analysis of 968 untreated AML adults from the 
Southwest Oncology Group trials demonstrated a consistent 
decrease with age in the likelihood of achieving complete 
remission (CR) and the likelihood of overall survival (OS). 
Among patients ,56, 56–65, 66–75, and .75 years the CR 
and OS rates were respectively: 64%, 46%, 39%, and 33% and 
18.8, 9.0, 6.9, and 3.5 months.4 These numbers are particu-
larly sobering considering that they reflect the outcomes of a 
selected minority (,30%) of older patients with AML who 
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Figure 4 Changes in outcome in older patients over 3 decades.
Note: Reprinted from Semin Hematol, 43(2), Burnett AK, Mohite U, Treatment of older patients with acute myeloid leukemia – new agents, 96–106.2 Copyright © 2006, 
with permission from Elsevier.
Abbreviations: AML, acute myeloid leukemia; MRC, Medical Research Council.
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were deemed “fit” to receive intensive therapy, and therefore, 
had a better prognosis. In contrast, the prognosis of the remain-
ing 70% deemed “unfit” for any leukemia-directed therapy, due 
to poor performance status, comorbid conditions, or various 
psychosocial considerations, is even more dismal.
Biology of AML in elderly patients
The results of clinical trials indicate that older patients with 
AML treated with intensive therapy suffer more complica-
tions, have a higher risk of early death, and a lower rate of 
remission, as well as a shorter progression-free survival and 
OS. As mentioned above, to a large extent, this is due to the 
particular biology of the disease in older patients.
Older patients with AML have a higher incidence of 
antecedent hematologic disorder and a higher incidence 
of adverse cytogenetics.5,6 Many cases of de novo AML in 
older patients actually resemble secondary AML, in that 
they are characterized by stem cell phenotypes, multilin-
eage involvement, and overexpression of genes conferring 
drug resistance.7 The multi-drug resistance 1 (MDR1) gene 
which encodes for P-glycoprotein, a chemotherapy efflux 
pump, occurs in 71% of older patients over 55 years of age, 
compared to only 35% of younger patients.8
A retrospective analysis of 968 AML patients from the 
Southwest Oncology Group trials was one of the more recent 
studies that emphasized the low incidence of favorable and 





relatively high incidence of unfavorable cytogenetics in older 
patients: favorable cytogenetics were found in 17% versus 
4% and unfavorable cytogenetics in 35% versus 51% of 
patients ,56 and .75 years old, respectively.4 The incidence 
of monosomal karyotype (MK), which carries a particularly 
dismal prognosis even among “unfavorable karyotypes,” was 
reported at about 20% in patients .60 years old, and only 4% 
in patients ,30 years old.9
Cytogenetic features are considered the most independent 
and strongest predictor of outcome in this disease across all 
ages.4,10,11 A UK Medical Research Council (MRC) AML11 
trial of 1,065 patients over 55 years old who were fit to toler-
ate intensive therapy validated the prognostic significance of 
cytogenetic groups devised for younger patients in the older 
patient population. Older patients with favorable karyotype 
accrued to the AML11 trial, accounting for 7% of the partici-
pants, enjoyed a CR rate of 72% and 5-year OS of 34%. In 
contrast, older patients with adverse karyotype, accounting 
for 13% of all patients in the trial, had a CR of 26% and a 
5-year OS of 2%.10 This data emphasized the need and pro-
vided the framework for stratified treatment approaches in 
older patient populations with this disease.
However, most elderly individuals have an intermediate 
cytogenetic risk, which the MRC AML11 trial defined as the 
presence of unfavorable, non-complex karyotypic abnormalities 
as well as the presence of normal karyotype. This is different 
from younger patients, in whom we can clearly appreciate the 
difference in outcome between patients with normal karyotype 
and patients with unfavorable non-complex karyotype.
The last few years brought about great progress in the 
characterization of cytogenetically normal AML. Among those 
patients, we can now define relatively homogeneous subsets 
of patients characterized by molecular events such as fms-like 
tyrosine kinase 3 (FLT3) gene mutation, nucleophosmin 1 
(NPM1) gene mutation, CCAAT/enhancer-binding protein 
alpha (CEBPA) gene mutation, and others. The presence of 
FLT3 internal tandem duplications (ITDs) in younger patients 
with AML has been associated with poor prognosis due to 
increased relapse rate and reduced remission duration and 
OS.12,13 A German study confirmed the poor prognostic bearing 
of FLT3-ITD mutation in elderly AML with comparable CR but 
significantly worse OS compared to wild-type patients.14 The 
Cancer and Leukemia Group B (CALGB) study, investigating 
the significance of FLT3-ITD mutation in older patients with 
AML, concurred with previous findings of shorter disease-free 
survival and OS.15 Interestingly, the impact of FLT3-ITD muta-
tion was observed particularly in patients aged 60–69 years 
(P,0.001) and not necessarily in those over 70 years old.15
In contrast, the presence of NPM1 mutation in the absence 
of FLT3 mutation is associated with improved prognosis in 
younger patients as well as older ones.16 The CALGB showed 
that in elderly patients over 60 years of age, those with NPM1 
mutation had a complete remission rate of 84%, as compared 
to 48% with wild-type NPM1.17 The 3-year OS rates were 
also higher in those with NPM1 mutations (35% versus [vs] 
8%). Similarly, a German study of 99 elderly AML patients 
demonstrated a higher CR rate of 80% in NPM1-positive 
patients as compared to 40.5% in wild-type NPM1. However, 
the authors found no significant difference in OS between the 
two groups.14
Interestingly, the German group led by Buchner, in their 
study of 1,284 AML patients receiving induction chemo-
therapy, reported a similar incidence of FLT3 and/or NPM1 
mutations in patients across all age groups.18 As with the 
overall AML population, there was poorer survival and remis-
sion duration in the older versus younger patients regardless 
of NPM1/FLT3 mutation status. However, older patients with 
NPM1 mutation performed better than those with wild-type 
NPM1, and those with FLT3 mutation performed worse than 
patients without mutated FLT3.18
Patient-related factors
The presence of patient-related factors, such as poor func-
tional status and comorbidities, greatly contribute to poor 
outcomes of treatment in elderly patients with AML. Due to 
these factors, older patients are often offered less intensive 
therapy, which may naturally be less effective. The pharma-
cokinetic and pharmacodynamic changes that occur with age 
result in delayed drug clearance, which may add to increased 
toxicity.6 The standard therapeutic strategies in older patients 
tend to induce deeper and more prolonged myelosuppression, 
which is likely a major determinant of early treatment-related 
morbidity and mortality seen in the course of induction in 
these patients. While older but otherwise fit and healthy 
patients may be able to tolerate these changes, the toxicity 
levels in those less fit and less healthy are often prohibitive. 
The 30-day mortality following aggressive induction chemo-
therapy for elderly patients with a performance status of $2 
increases with age and ranges from 18%–24% for patients 
aged 56–65 years to 50%–82% for patients older than 75 
years.4 Thus, novel treatment strategies developed specifically 
for older patients and studied in elderly-specific clinical tri-
als are desperately needed. Such trials should incorporate a 
comprehensive assessment of older adults in regards to tumor 
biology as well as comorbidities and functional impairments. 
Last but not least, we should also start appreciating other 
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psychosocial factors such as the availability of caretakers and 
proximity to trial enrollment centers.19
Rationale for treating  
elderly AML patients
Given the suboptimal response to treatment and substantial 
toxicity associated with intensive therapy for elderly AML 
patients, the potential benefits of such measures have been 
repeatedly questioned. Using data from the SEER program 
and Medicare administrative claims, Menzin et al reported that 
between 1991 and 1996, only 30% of newly diagnosed AML 
patients aged 65 years and older underwent  chemotherapy.20 
The median OS for all patients was only 2 months and 2-year 
survival was only 6%. However, the median survival of patients 
who received chemotherapy was 8 months.20 The follow-up 
SEER–Medicare data from 1999–2002 found that adminis-
tration of chemotherapy to elderly AML patients increased 
to 36%.21 As expected, the median survival in the treated 
group was longer than the untreated group (6.1 months vs 
1.7 months). Obviously, such data is difficult to interpret, as 
patients who were offered treatment were likely younger and 
more fit than those who did not.
However, newer data generated by randomized trials 
and new, larger database analyses definitely indicate that 
elderly patients with AML treated with aggressive therapy 
can achieve durable remissions, and that this translates into 
prolongation of survival and good quality of life.22–24
The landmark publication by Lowenberg et al compared 
immediate-intensive chemotherapy versus supportive care 
with mild cytoreductive chemotherapy for AML-related 
symptom relief in patients older than 65 years of age.22 
Intensive chemotherapy with daunorubicin, vincristine, and 
cytarabine was associated with high CR rates (58% vs 0%), 
longer median survival (21 weeks vs 11 weeks), and improved 
disease-free survival at 2.5 years (13% vs 0%). More impor-
tantly, the authors showed that there was no difference in 
the percentage of days the patient spent in the hospital. 
Population-based data from the Swedish Acute Leukemia 
Registry strongly suggests that standard intensive chemo-
therapy improves early mortality and long-term  survival 
compared with palliation.23 A more recent publication from 
Japan also found intensive chemotherapy in elderly AML 
was beneficial.24
Although better than supportive care, the results of 
intensive therapy in elderly patients remain disappointing. 
 Numerous clinical trials have looked into increasing or atten-
uating doses, adding or replacing drugs, and utilizing growth 
factors – without much success. Lowenberg et al conducted a 
Phase III study comparing the standard “7+3 regimen” with 
standard-dose (45 mg/m2) versus intensified-dose (90 mg/m2) 
of daunorubicin in AML patients aged 60 years or older.25 
Although there was no overall difference in outcome between 
the two groups, the intensified-dose was associated with 
increased response rates and survival benefit in a subset 
of patients aged 60–65 years. Schlenk et al evaluated the 
impact of all-trans retinoic acid (ATRA) as an adjunct to 
induction and consolidation chemotherapy in AML patients 
60 years or older.26 The addition of ATRA during induction 
 chemotherapy significantly increased CR (52% vs 39%), 
event-free survival (EFS), and OS rates. More recently, 
a French study evaluated the effect of adding gemtuzumab 
ozogamicin (GO), an anti-CD33 antibody conjugate, to 
standard chemotherapy regimens in newly diagnosed 
AML patients aged 50–70 years.27 Although the CR 
rates were similar in both groups, the addition of GO 
significantly improved the 2-year EFS (40.8% vs 17.1%) 
and OS (53.2% vs 21.9%) rates. Similarly, in the UK AML 16 
study, the addition of GO on day 1 of induction chemotherapy 
showed a small but significant 3-year OS benefit (25% vs 
20%) with no increase in toxicity.28 Both these studies have 
generated renewed interest in gemtuzumab, which was vol-
untarily withdrawn by Pfizer from the US market in 2010 
due to lack of efficacy in the presence of enhanced toxicity.29 
Regardless, aggressive therapy for older patients with AML 
remains only modestly effective overall.30
Perhaps the greatest achievement of the past decade 
in this field was a realization that patients unfit to receive 
aggressive therapy can still benefit from leukemia-specific 
chemotherapy, albeit at lower doses, which still offers survival 
advantage and improved quality of life.
An MRC AML 14 trial randomly selected 217 elderly 
AML patients deemed unsuitable for intensive chemotherapy 
to receive low-dose cytarabine or hydroxyurea with best 
supportive care.31 Low-dose cytarabine was associated with 
significantly higher CR rates (18% vs 1%) and 1-year OS 
(25% vs 6%). Remarkably, the toxicity scores and require-
ment for supportive care did not differ between trial arms. 
Additionally, the benefit in this trial was limited to patients 
with favorable and intermediate risk cytogenetics, and the 
overall prognosis remained quite poor with the OS for the 
entire study population being 13% at 1 year, 4% at 2 years, 
and ,1% at 3 years.
Numerous efforts have been undertaken to create treat-
ment options that would be tolerable but also more effective. 
Clofarabine seemed to have quite a favorable toxicity profile 
and has been tested extensively in American and European 





trials.32,33 The trials yielded encouraging results, particu-
larly in older patients with AML associated with poor risk 
 karyotypes. However, despite a few unique toxicities, the 
safety profile proved very comparable with standard intensive 
chemotherapy regimens. Clofarabine is currently being com-
pared with the standard of care combination of anthracycline 
and cytarabine in an Eastern Cooperative Oncology Group 
(ECOG)-led Intergroup Phase III Randomized Trial.34
Demethylating agents offer a novel mechanism of action, 
acceptable toxicity profile, and proven efficacy in myelodys-
plastic syndromes, which makes them great candidates for 
treatment in this setting. A subset analysis of a large Phase III 
randomized trial compared the effects of azacitidine in elderly 
patients with low bone marrow blast counts (20%–30%) with 
conventional care regimens (CCR), which included intensive 
chemotherapy (IC), low-dose cytarabine (LDAC), or best sup-
portive care (BSC).35 Of the 113 elderly patients, with a median 
age of 70 years, 86% were considered unfit for IC. In the CCR 
group, 47% received BSC, 34% received LDAC, and only 19% 
received IC. The authors found that azacitidine significantly 
prolonged OS (24.5 months vs 16.0 months).35 Notably the 
2-year survival in patients with adverse cytogenetics was 
strongly in favor of azacitidine (38% vs 0%). Decitabine has 
also been evaluated in elderly AML patients unsuitable for 
intensive chemotherapy.36–38 In a multicenter Phase III trial, 485 
elderly AML patients aged $65 years were randomly assigned 
to receive either decitabine 20 mg/m2 per day as a 1-hour 
intravenous infusion for 5 consecutive days every 4 weeks or 
treatment choice (TC) (supportive care or cytarabine 20 mg/
m2 per day as a subcutaneous injection for 10 consecutive days 
every 4 weeks).38 Treatment with decitabine was associated 
with a higher CR rate and better median OS (7.7 months vs 
5.0 months). Although the difference in survival was not 
statistically significant, and thus, the study failed to meet its 
primary objective, this data eventually led to the approval of 
decitabine for the treatment of AML in adults 65 years or older 
by the European Commission. The drug was not approved for 
the treatment of AML in the US although further studies of 
decitabine in the US resulted in the creation of a prolonged 
10-day dosing regimen, which may prove more effective than 
the original 5-day regimen adapted from myelodysplastic 
syndrome (MDS).37 The 10-day regimen is currently being 
investigated by a CALGB-led intergroup randomized trial.39
A few other agents are in the advanced stages of develop-
ment, including but not limited to CPX-351, which fixes a 5:1 
ratio of cytarabine to daunorubicin within a liposomal carrier and 
a novel topoisomerase II inhibitor, vosaroxin.40,41 Hopefully, the 
next few years will see significant progress in the development of 
more effective and less toxic regimens. However, it is not appar-
ent to what extent these treatment modalities will be available 
to help older patients with AML who are unable to travel to the 
chemotherapy treatment centers daily to receive their decitabine 
or every other day to check their blood counts and receive their 
blood products. In this regard, sapacitabine, a novel oral nucleo-
side analog holds great promise as it can be given orally at home 
and may not require intensive supportive care.
Profile of sapacitabine
Sapacitabine (CS-682) is an oral palmitoyl derivative of 
2′-C-Cyano-2′-deoxy-b-D-arabino-pentofuranosylcytosine 
(CNDAC), a deoxycytidine analog with a novel DNA-strand-
breaking mechanism of action (Figure 5).42,43 The fatty-acid 
side chain on the N4 group of the cytosine moiety improves 
the oral bioavailability of sapacitabine and reduces inactiva-
tion by deamination. Upon oral administration, sapacitabine 
is converted to its active metabolite, CNDAC, by amidases 
and esterases in the plasma, gut, and liver. CNDAC is then 
phosphorylated to CNDAC-triphosphate by intracellular 
deoxycytidine kinase before being incorporated into cellular 
DNA. Following its integration into DNA, CNDAC inhibits 
DNA polymerases, resulting in cessation of DNA-strand 
elongation. In addition, CNDAC promotes induction of 
 single-strand DNA breaks, which are converted to double-
strand DNA breaks, thus activating the double-stranded DNA 
(dsDNA) repair pathway and resulting in arrest at the G2/M 
phase. This mechanism is unique and not seen in other deoxy-
cytidine analogs such as cytarabine or gemcitabine.44,45
Preclinical studies
Preclinical studies have demonstrated the potential of sapac-
itabine and CNDAC for antitumor activity. Sapacitabine dis-
plays cytotoxic activity across a range of concentrations in a 
variety of human solid tumor cell lines.46 CNDAC was found 
to be more effective than cytarabine in murine and human 
tumor cell lines derived from lung, stomach, and osteosar-
coma samples.47 However, sapacitabine appeared to be more 
potent than CNDAC against human organ tumor xenografts at 
a wide dose range and with low toxicity.43 Sapacitabine was 
also effective against P388 human leukemia cells resistant 
to mitomycin-C, vincristine, 5-fluorouracil, or cisplatin in 
syngeneic mice.43 In an orthotopic human pancreatic cancer 
mouse model, sapacitabine suppressed the rate of primary 
tumor growth, decreased the formation of metastases, and 
significantly prolonged survival at all doses compared with 
untreated animals.48,49 The combination of sapacitabine and 
histone deacetylase (HDAC) inhibitors induced a significant 




















Figure 5 Structure of sapacitabine and CNDAC.
Abbreviation: CNDAC, 2′-C-Cyano-2′-deoxy-b-D-arabino-pentofuranosylcytosine.
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increase in apoptosis in an AML cell line, MV4-11, in vitro 
and in an MV4-11 mouse xenograft model in vivo.50
Clinical trials
Encouraging results from preclinical studies have led to 
several Phase I studies of sapacitabine in solid tumors. 
 Sapacitabine was administered orally to 48 patients with 
refractory solid tumor malignancies.51 No objective tumor 
response was noted, although eleven patients achieved 
disease stability. More importantly, the drug was very well-
tolerated and had very few side effects, with the dose-limiting 
toxicity being neutropenia. A second study of 40 patients 
with advanced solid tumors also did not demonstrate any 
tumor response, although six patients experienced disease 
stability.52 Because of its unique mechanism of action, and a 
defined dose-limiting toxicity of neutropenia in solid tumors, 
sapacitabine became an attractive agent to investigate in 
hematological malignancies.
Kantarjian et al conducted a Phase I trial of sapacitabine 
in 47 patients aged 18 years or older with refractory-relapsed 
acute leukemia, myelodysplastic syndrome, or untreated dis-
ease, who received sapacitabine in escalating doses from 75 mg 
to 375 mg twice daily for 7 days (n=35) and from 375 mg to 
475 mg twice daily for 3 days per week for 2 weeks (n=12).53 
In both dosing regimens, the dose-limiting non-hematological 
toxicity was gastrointestinal symptoms of diarrhea and neutro-
penic colitis. The overall response rate was 28% (n=13), with 
four patients (9%) achieving complete remission. The esti-
mated 4-week mortality was only 4%. This study established 
a maximum tolerated dose of 325 mg twice daily for 7 days or 
425 mg twice daily on days 1 to 3 weekly for 2 weeks.
The encouraging anti-leukemic activity of sapacitabine, its 
reasonable safety profile, and more importantly, its ease of oral 
administration, makes sapacitabine an ideal drug for study in 
the elderly AML population. A multi-institutional randomized 
Phase II study recruited 105 AML patients .70 years who 
were either treatment-naïve (n=86) or at first relapse (n=19).54 
The patients were randomized to a three-arm trial of sapacit-
abine at 200 mg twice daily for 7 days every 28 days (Arm A), 
at 300 mg on the same schedule (Arm B), or at 400 mg twice 
daily for 3 days per week for 2 weeks, every 28 days (Arm 
C). The overall 1-year survival was 35%, 10%, and 30% and 
median OS was 197, 102, and 213 days in Arms A, B, and C, 
respectively. Although sapacitabine was well-tolerated with 
a 30-day and 60-day mortality of 13% and 26%, respectively, 
frequent dose reduction was required due to myelosuppres-
sion, which could potentially affect its efficacy.
The encouraging results of sapacitabine have led to further 
trials evaluating sapacitabine in combination with other cur-
rently available agents, such as decitabine. In a pilot Phase I/II 
study, 46 elderly AML patients were treated with alternating 
cycles of decitabine 20 mg/m2 intravenously daily ×5 days of 
a 4-week cycle (odd cycles) and sapacitabine 300 mg orally 
twice daily ×3 days/week of a 4-week cycle (even cycles).55 
The median age was 77 years (range 70–90 years) and the 
median OS was 238 days, approximately 8 months. The 3-, 
6-, 12-, and 18-month survival rates were 83%, 65%, 35%, 
and 26%, respectively. Nineteen patients (41%) responded 
with ten CRs, four partial responses (PRs), and five major 
hematological improvements (HIs). The median response 





time was two cycles, ie, one cycle of decitabine and one cycle 
of sapacitabine (range 1–10). Thirty-day mortality from all 
causes was 4%.
Ongoing clinical trials
The safety and efficacy of the sequential combination 
of decitabine and sapacitabine has led to the creation of 
a Study of Oral Sapacitabine in Elderly Patients with 
Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS); 
a pivotal, multicenter, randomized Phase III study comparing 
sapacitabine and/or decitabine as front-line treatment of 
elderly patients aged 70 years or older with newly diag-
nosed AML who are not candidates for intensive induction 
chemotherapy.56 Patients receive either sapacitabine admin-
istered in alternating cycles with decitabine, or decitabine 
alone. The primary efficacy endpoint is OS. The study is 
expected to complete accrual in April 2015.
Conclusion
Decisions regarding the optimal treatment in individual older 
patients with AML require consideration of multiple factors 
and remain quite challenging. As reviewed above, numerous 
studies published in recent years consistently demonstrated 
that a specific anti-leukemia therapy results in improved sur-
vival and quality of life when compared with best supportive 
care. We no longer need “to protect” elderly patients from 
therapy. However, improvements observed with currently 
available treatment approaches are modest at best and the 
overall prognosis remains poor.
This invites renewed efforts to investigate anti-leukemic 
therapies specifically designed to treat elderly patients with 
AML; therapies that will take into account the different 
biology of the disease as well as offer favorable toxicity 
profiles and relative ease of administration. The future of 
leukemia treatment clearly lies in targeted therapy. Many 
of the newer targeted drugs are better tolerated than con-
ventional chemotherapy and should be well-tolerated by 
younger as well as older patients. At this time, however, 
having drugs that could be taken at home and that could 
provide improvement in survival and quality of life would 
be greatly appreciated not only by patients but also by their 
physicians. The SEAMLESS trial fulfills a great need as it 
strives to provide access to potentially effective therapy to 
patients over 70 years old. These patients, due to their age, 
comorbid conditions, and/or inadequate social support, 
are offered treatment only occasionally. Home therapy 
should at least partly alleviate the need for caregivers and 
 transportation. With all this in mind, little is known about the 
true impact of such treatment delivery on the patient and/or 
family. It will be very interesting to learn if such treatment 
will truly improve the lives of patients and their families. 
The medical community is awaiting the results from this 
trial with great interest.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Howlader N, Noone AM, Krapcho M, et al (editors). SEER Cancer 
Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 
2013.
 2. Burnett AK, Mohite U. Treatment of older patients with acute myeloid 
leukemia – new agents. Semin Hematol. 2006;43(2):96–106.
 3. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, 
Bjorkholm M. Improved patient survival for acute myeloid leukemia: 
a population-based study of 9729 patients diagnosed in Sweden between 
1973 and 2005. Blood. 2009;113(16):3666–3672.
 4. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid 
leukemia. Blood. 2006;107(9):3481–3485.
 5. Hoyle CF, de Bastos M, Wheatley K, et al. AML associated with previous 
cytotoxic therapy, MDS or myeloproliferative disorders: results from 
the MRC’s 9th AML trial. Br J Haematol. 1989;72(1):45–53.
 6. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the 
elderly: a review. Br J Haematol. 2011;152(5):524–542.
 7. Head DR. Revised classification of acute myeloid leukemia. Leukemia. 
1996;10(11):1826–1831.
 8. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the 
elderly: assessment of multidrug resistance (MDR1) and cytogenetics 
distinguishes biologic subgroups with remarkably distinct responses 
to standard chemotherapy. A Southwest Oncology Group study. Blood. 
1997;89(9):3323–3329.
 9. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. 
 Prognostic impact of monosomal karyotype in young adult and elderly 
acute myeloid leukemia: the Southwest Oncology Group (SWOG) 
experience. Blood. 2010;116(13):2224–2228.
 10. Grimwade D, Walker H, Harrison G, et al. The predictive value of hier-
archical cytogenetic classification in older adults with acute myeloid leu-
kemia (AML): analysis of 1065 patients entered into the United Kingdom 
Medical Research Council AML11 trial. Blood. 2001;98(5):1312–1320.
 11. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add 
to other prognostic factors predicting complete remission and long-
term outcome in patients 60 years of age or older with acute myeloid 
leukemia: results from Cancer and Leukemia Group B 8461. Blood. 
2006;108(1):63–73.
 12. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of 
activating FLT3 mutations in younger adults (16 to 60 years) with acute 
myeloid leukemia and normal cytogenetics: a study of the AML Study 
Group Ulm. Blood. 2002;100(13):4372–4380.
 13. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic signifi-
cance of FLT3 internal tandem duplication and tyrosine kinase domain 
mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 
2005;19(8):1345–1349.
 14. Scholl S, Theuer C, Scheble V, et al. Clinical impact of nucleophos-
min mutations and Flt3 internal tandem duplications in patients 
older than 60 yr with acute myeloid leukaemia. Eur J Haematol. 
2008;80(3):208–215.
 15. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem 
duplication associates with adverse outcome and gene- and microRNA-
expression signatures in patients 60 years of age or older with primary 
cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia 
Group B study. Blood. 2010;116(18):3622–3626.




Sapacitabine in elderly patients with AML
 16. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin 
(NPM1) predicts favorable prognosis in younger adults with acute 
myeloid leukemia and normal cytogenetics: interaction with other gene 
mutations. Blood. 2005;106(12):3740–3746.
 17. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact 
of NPM1 mutations in older patients with cytogenetically normal de 
novo acute myeloid leukemia and associated gene- and microRNA-
expression signatures: a Cancer and Leukemia Group B study. J Clin 
Oncol. 2010;28(4):596–604.
 18. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and 
chemotherapy dose response in acute myeloid leukemia: a study by the 
German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 
2009;27(1):61–69.
 19. Gross CP, Herrin J, Wong N, Krumholz HM. Enrolling older persons in 
cancer trials: the effect of sociodemographic, protocol, and recruitment 
center characteristics. J Clin Oncol. 2005;23(21):4755–4763.
 20. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and 
costs of acute myeloid leukemia among the elderly. Arch Intern Med. 
2002;162(14):1597–1603.
 21. Menzin J, Boulanger L, Karsten V, Cahill AL, Earle CE. Effects of 
initial treatment on survival among elderly AML patients: findings 
from the SEER-Medicare Database. ASH Annual Meeting Abstracts. 
2006;108:1973.
 22. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive 
remission-induction chemotherapy in elderly patients of 65+ years with 
acute myeloid leukemia: a randomized phase III study of the European 
Organization for Research and Treatment of Cancer Leukemia Group. 
J Clin Oncol. 1989;7(9):1268–1274.
 23. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid 
leukemia: real world data on decision to treat and outcomes from the 
Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187.
 24. Oshima K, Takahashi W, Asano-Mori Y, et al. Intensive chemotherapy 
for elderly patients with acute myelogeneous leukemia: a propensity 
score analysis by the Japan Hematology and Oncology Clinical Study 
Group (J-HOCS). Ann Hematol. 2012;91(10):1533–1539.
 25. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose dauno-
rubicin in older patients with acute myeloid leukemia. N Engl J Med. 
2009;361(13):1235–1248.
 26. Schlenk RF, Frohling S, Hartmann F, et al. Phase III study of all-trans 
retinoic acid in previously untreated patients 61 years or older with 
acute myeloid leukemia. Leukemia. 2004;18(11):1798–1803.
 27. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin 
on survival of adult patients with de-novo acute myeloid leukaemia 
(ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 
2012;379(9825):1508–1516.
 28. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozo-
gamicin to induction chemotherapy improves survival in older patients 
with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–3931.
 29. US Food and Drug Administration [webpage on the Internet]. 
 Gemtuzumab ozogamicin [last updated June 22, 2010]. Available from: 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProdu
ctsandTobacco/CDER/ucm216790.htm. Accessed March 11, 2014.
 30. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. 
Oncologist. 2009;14(3):222–232.
 31. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose 
cytarabine and hydroxyurea with or without all-trans retinoic acid for 
acute myeloid leukemia and high-risk myelodysplastic syndrome in 
patients not considered fit for intensive treatment. Cancer. 2007;109(6): 
1114–1124.
 32. Burnett AK, Russell NH, Kell J, et al. European development of clo-
farabine as treatment for older patients with acute myeloid leukemia 
considered unsuitable for intensive chemotherapy. J Clin Oncol. 
2010;28(14):2389–2395.
 33. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine 
monotherapy in previously untreated older adults with acute myeloid 
leukemia and unfavorable prognostic factors. J Clin Oncol. 2010;28(4): 
549–555.
 34. ClinicalTrials/gov. Eastern Cooperative Oncology Group. Clofarabine 
or Daunorubicin Hydrochloride and Cytarabine Followed By Decit-
abine or Observation in Treating Older Patients With Newly Diagnosed 
Acute Myeloid Leukemia. Available from: http://clinicaltrials.gov/show/
NCT01041703. NLM identifier: NCT01041703. Accessed April 3, 
2014.
 35. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs 
overall survival compared with conventional care regimens in elderly 
patients with low bone marrow blast count acute myeloid leukemia. 
J Clin Oncol. 2010;28(4):562–569.
 36. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, 
phase II study of decitabine for the first-line treatment of older 
patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4): 
556–561.
 37. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b 
predictive significance in older AML patients treated with a 10-day 
schedule of decitabine. Proc Nat Acad Sci U S A. 2010;107(16): 
7473–7478.
 38. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, ran-
domized, open-label, phase III trial of decitabine versus patient choice, 
with physician advice, of either supportive care or low-dose cytarabine 
for the treatment of older patients with newly diagnosed acute myeloid 
leukemia. J Clin Oncol. 2012;30(21):2670–2677.
 39. ClinicalTrials.gov. National Cancer Institute (NCI). Decitabine With 
or Without Bortezomib in Treating Older Patients With Acute Myeloid 
Leukemia. Available from: http://clinicaltrials.gov/show/NCT01420926. 
NLM Identifier: NCT01420926. Accessed April 3,2014.
 40. Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of 
CPX-351; a nano-scale liposomal fixed molar ratio formulation of 
cytarabine:daunorubicin, in patients with advanced leukemia. Leuk 
Res. 2012;36(10):1283–1289.
 41. Freeman C, Keane N, Swords R, Giles F. Vosaroxin: a new valuable tool 
with the potential to replace anthracyclines in the treatment of AML? 
Expert Opin Pharmacother. 2013;14(10):1417–1427.
 42. Matsuda A, Nakajima Y, Azuma A, Tanaka M, Sasaki T. Nucleosides 
and nucleotides. 100. 2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosyl-
cytosine (CNDAC): design of a potential mechanism-based DNA-
strand-breaking antineoplastic nucleoside. J Med Chem. 1991;34(9): 
2917–2919.
 43. Hanaoka K, Suzuki M, Kobayashi T, et al. Antitumor activity and novel 
DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-
deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl 
derivative (CS-682). Int J Cancer. 1999;82(2):226–236.
 44. Azuma A, Huang P, Matsuda A, Plunkett W. 2′-C-cyano-2′-deoxy-1-
beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside 
analog that causes both DNA strand breaks and G(2) arrest. Mol 
 Pharmacol. 2001;59(4):725–731.
 45. Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related 
and DNA-dependent protein kinase cooperate in G2 checkpoint 
activation by the DNA strand-breaking nucleoside analogue 2′-C-
cyano-2′-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer 
Ther. 2008;7(1):133–142.
 46. Serova M, Galmarini CM, Ghoul A, et al. Antiproliferative effects of 
sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human 
cancer cells. Br J Cancer. 2007;97(5):628–636.
 47. Tanaka M, Matsuda A, Terao T, Sasaki T. Antitumor activity of a novel 
nucleoside, 2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosylcytosine 
(CNDAC) against murine and human tumors. Cancer Lett. 1992;64(1): 
67–74.
 48. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. 
Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluo-
rescent orthotopic model of human pancreatic cancer. Cancer Res. 
2004;64(5):1828–1833.
 49. Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM. 
Selective antimetastatic activity of cytosine analog CS-682 in a red 
fluorescent protein orthotopic model of pancreatic cancer. Cancer Res. 
2003;63(17):5521–5525.
Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts Ser-
vice’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.






 50. Green SR, Choudhary AK, Fleming IN. Combination of sapacitabine 
and HDAC inhibitors stimulates cell death in AML and other tumour 
types. Br J Cancer. 2010;103(9):1391–1399.
 51. Gilbert J, Carducci MA, Baker SD, Dees EC, Donehower R. A Phase I 
study of the oral antimetabolite, CS-682, administered once daily 5 days 
per week in patients with refractory solid tumor malignancies. Invest 
New Drugs. 2006;24(6):499–508.
 52. Delaunoit T, Burch PA, Reid JM, et al. A phase I clinical and pharma-
cokinetic study of CS-682 administered orally in advanced malignant 
solid tumors. Invest New Drugs. 2006;24(4):327–333.
 53. Kantarjian H, Garcia-Manero G, O’Brien S, et al. Phase I clinical 
and pharmacokinetic study of oral sapacitabine in patients with acute 
leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28(2): 
285–291.
 54. Kantarjian H, Faderl S, Garcia-Manero G, et al. Oral sapacitabine for the 
treatment of acute myeloid leukaemia in elderly patients: a randomised 
phase 2 study. Lancet Oncol. 2012;13(11):1096–1104.
 55. Ravandi F, Kadia TM, Borthakur G, et al. Pooled analysis of elderly 
patients with newly diagnosed AML treated with sapacitabine and 
decitabine administered in alternating cycles. Poster presented at: Blood 
(ASH Annual Meeting Abstracts); December 9, 2012; Atlanta, Georgia: 
Abst 2630.
 56. ClinicalTrials.gov. Cyclacel Pharmaceuticals, Inc. A Study of Oral 
Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid 
Leukemia (SEAMLESS). Available from: http://clinicaltrials.gov/show/
NCT01303796. NLM Identifier: NCT01303796. Accessed April 3, 
2014.
